AVROBIO, Inc. (AVRO)
Company Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.
Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.
The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Jun 21, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Erik John Ostrowski M.B.A. |
Contact Details
Address: 100 Technology Square, 6th Floor Cambridge, Massachusetts 02139 United States | |
Phone | 617.914.8420 |
Website | avrobio.com |
Stock Details
Ticker Symbol | AVRO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001681087 |
CUSIP Number | 05455M100 |
ISIN Number | US05455M1009 |
Employer ID | 81-0710585 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Erik John Ostrowski M.B.A. | President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer |
Dr. Azadeh Golipour Ph.D. | Chief Technology Officer |
Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer |
Jeffrey Medin Ph.D. | Scientific Founder |
Steven N. Avruch J.D. | Chief Legal Officer and Secretary |
Scott Gottesman | Vice President of Human Resource |
Kirsten Dupuis | Chief of Staff |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | S-4/A | Filing |
Mar 14, 2024 | 10-K | Annual Report |
Feb 23, 2024 | SCHEDULE 13G | Filing |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | S-4 | Filing |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 30, 2024 | 425 | Filing |
Jan 30, 2024 | 425 | Filing |